Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder

Major Depressive Disorder Clinical Trial

Official title:

A 12-Month Prospective Randomized Dual-Arm Pilot Study of Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01415154
• Other study ID #: 44-03001-000
• Status: Completed
• Phase: N/A
• Start date: August 2011
• Est. completion date: July 2014

Study information

• Verified date: September 2021
• Source: Neuronetics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of scheduled maintenance Transcranial Magnetic Stimulation (TMS) treatment compared to on-demand TMS treatment for symptomatic worsening in patients who have shown a clinical response to acute TMS treatment.

Description:

This is a 12-month maintenance treatment study for patients who have responded to a 6 week course of acute TMS treatment for major depressive disorder (MDD). The study will seek to assess the change in depressive symptomatology across the duration of maintenance treatment using observer and self-administered efficacy measures. Describe the efficacy of TMS re-introduction in patients not receiving maintenance pharmacotherapy who show a recurrence of depressive symptoms. Assess the safety and durability of acute TMS therapy followed by maintenance TMS treatment for up to 12 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 67
• Est. completion date: July 2014
• Est. primary completion date: September 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Primary diagnosis by DSM-IV criteria for Major Depressive Episode, single episode or recurrent course of illness, with the additional stipulation of a duration for this episode of = 4 weeks and CGI-S = 4.
• Duration of current episode of depression = 3 years (the definition of an episode is demarcated by a period of = 2 months when the patient did not meet full criteria for the DSM-IV definition of Major Depressive Episode.
• Capable and willing to provide informed consent.
• Signed HIPAA authorization.
• Able to adhere with the treatment schedule, and withdrawal of ongoing pharmacotherapy.
• If currently taking antidepressant pharmacotherapy, must be clinically appropriate to discontinue treatment with those agents.

Exclusion Criteria:

• Investigators, site personnel directly affiliated with this study, and their immediate families (immediate family is defined as a spouse, parent, child or sibling, whether by birth or legal adoption).
• Individuals diagnosed by the Investigator with the following conditions (current

unless otherwise stated):

• Depression secondary to a general medical condition, or substance- induced;
• Seasonal pattern of depression as defined by DSM-IV;
• History of substance abuse or dependence within the past year except nicotine and caffeine);
• Any psychotic disorder (lifetime), including schizoaffective disorder, or major depression with psychotic features in this or previous episodes;
• Bipolar disorder;
• Eating disorder (current or within the past year);
• Obsessive compulsive disorder (lifetime); or
• Post-traumatic stress disorder (current or within the past year).
• An Axis II Personality Disorder, which in the judgment of the Investigator may hinder the patient in completing the procedures required by the study protocol.
• Individuals with a clinically defined neurological disorder or insult including, but

not limited to:

• Any condition likely to be associated with increased intracranial pressure;
• Space occupying brain lesion;
• History of cerebrovascular accident;
• Transient ischemic attack within two years;
• Cerebral aneurysm;
• Dementia;
• Parkinson's disease;
• Huntington's chorea;
• Multiple sclerosis.
• Increased risk of seizure for any reason, including but not limited to prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or history of significant head trauma with loss of consciousness for = 5 minutes.
• History of treatment with Vagus Nerve Stimulation.
• Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Disease
• Major Depressive Disorder

Intervention

Device:
• NeuroStar TMS
NeuroStar TMS treatmant - 120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.

Locations

Country	Name	City	State
United States	Sheppard Pratt Health System	Baltimore	Maryland
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Rush University Medical Center	Chicago	Illinois
United States	Premier Psychiatric Group, L.L.C.	Lincoln	Nebraska
United States	Center for Anxiety and Depression	Mercer Island	Washington
United States	Butler Hospital	Providence	Rhode Island

Sponsors (1)

Lead Sponsor	Collaborator
Neuronetics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Examining the proportion of patients maintaining a sustained response throughout a 12 month maintenance treatment phase.	Sustained response is defined as not requiring TMS reintroduction at every observation point during the maintenance phase.	12 month evaluation
Secondary	Compare the average time to first reintroduction of TMS between the two maintenance treatment arms.	Change in depressive symptomatology will be assessed across the duration of maintenance treatment using observer and self-administered efficacy measures.	12 Month evaluation